Youn H Kim
Publication Details
-
Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab.
J Am Acad Dermatol. 2008; (6): 953-7
Optimal treatment of indolent primary cutaneous B-cell lymphoma (CBCL), marginal zone lymphoma, and follicle center lymphoma, presenting as multiple lesions, has yet to be established. Rituximab is a chimeric monoclonal IgG1 antibody directed against the CD20 antigen of B cells. Clinical efficacy of systemic rituximab in CBCL has yet to be established.
Help
Trial Administration